| Detailed information |
|---|
| CancerLivER ID | 2110 |
| Biomarker | DHCR24 Auto-antibody |
| Biomarker Name/Symbol (given in Publication) | DHCR24 Auto-antibody |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | A potential noninvasive biomarker for HCV-related liver disease and may facilitate the diagnosis of PIVKA-II and AFP-negative HCC and validated on independent dataset |
| Experimental Condition | HCC vs Chronic heaptitis (CHV)/healthy/Liver cirrhosis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | DHCR24 was up-regulated in HCV-positive, but not HBV-positive tissues or HBV-negative, HCV-negative HCC |
| Level of significance | p < 0.0001 |
| Source | Serum |
| PMID | 26288822 |
| Type of Biomarker | Prognostic |
| Pathway | Multiple pathway (chronic inflammation, cirrhosis, cell death, and proliferation) |
| Cohort | 395 HCV-positive patients, including 133 chronic hepatitis (CHC), 85 liver cirrhosis (LCC), and 177 HCC (HCC-C) patients; 232 hepatitis B virus (HBV)-positive patients, including 103 chronic hepatitis (CHB), 56 liver cirrhosis (LCB), and 73 HCC (HCC-B) patients; and 24 healthy controls |
| Sensitivity | 70.06 |
| Specificity | 100 |
| Accuracy | NA |
| AUC | 0.98 |
| Disease | Human HCV,CHC, LCC HCC-B, HCC-C, CHB |
| Year of Publication | 2015 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |